Miller tested the effects of a TNF-α antagonist (infliximab) in patients with treatment-resistant depression.
This was not a clinical trial, he emphasized, but a way to better understand the cytokine hypothesis of depression. Ultimately, they found that use of the drug reduced HAM-D scores overall equal to those found with placebo. However, the subset of patients with higher baseline CRP (>5 mg/L) levels demonstrated a greater treatment response, 62 percent among treated patients compared with 33 percent of those on placebo.